Lineage Cell Therapeutics, Inc.
LCTX· NYSE
LCTXLineage Cell Therapeutics, Inc.
Filed Mar 5, 2026 · 10-K · 64 days after period end · 0001193125-26-093992
derived · Computed from the longer spans the company filed.
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023 | Q4 2022 |
|---|---|---|---|---|
| Revenue | $6.61M | $2.87M | $2.09M | $1.92M |
| Net Income | $851.00K | -$3.27M | -$4.78M | -$6.35M |
| EPS Diluted | — | — | -$0.03 | -$0.03 |
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2025 · filed Mar 5, 2026 · 64 d after period end
